The RTOG Outcomes Model: economic end points and measures

Bibliography

• JAAKKIMAINEN L, GOODWIN PJ,PATER J, WARDE P, MURRAY N, RAPP E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. Olin. Oncol.(1990) 8(8):1301–1309.
   Google Scholar
• BRUNER DW, MOVSAS B, KONSKI A et al: Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model. Qual. Life Res. (2004) (In Press).
   Google Scholar
• NEYMARK N, ADRIAENSSEN I, GORLIA T, CALEO S, BOLLA M:Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locallyadvanced prostate cancer. Health Econ.(2002) 11(3):233–248.
   PubMedGoogle Scholar
• •A good landmark article.
   Google Scholar
• NEYMARK N, KIEBERT W, TORFS Ket al.: Methodological and statistical issues of quality of life (QoL) and economic evaluations in cancer clinical trials: Report of a workshop. Eur: .1. Cancer (1998) 9:1317–1333.
   Google Scholar
• OWEN JB, GRIGSBY PW,CALD WELL TM et al.: Can costs be measured and predicted by modeling withina cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90–03 and 91–04. Int. J. Radiat. Once]. Biel Phys. (2001) 49(3):633–639.
   Google Scholar
• •A good landmark article.
   Google Scholar
• MURRAY KJ, NELSON DF, SCOTT Cet al.: Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83–02. Intl: Radiat. Once]. Biel Phys. (1995) 31(3):453–459.
   Google Scholar
• •A good landmark article.
   Google Scholar
• KONSKI A, BRACY P, WEISS S, GRIGSBY P: Cost-utility analysis of a malignant glioma protocol. Int. Radiat. Once]. Biel Phys. (1997) 39(3):575–578.
   PubMedGoogle Scholar
• MOVSAS B, SCOTT C, SAUSE W et al: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.Radiat. Omni Biel Phys. (1999) 45(5):1143–1149.
   Google Scholar
• KONSKI A, SCOTT C, MOVSAS B et al: Cost-utility analysis of various treatments for non-small cell carcinoma of the lung. Eur: J. Cancer (2000) 36(3):19.
   Google Scholar
• KONSKI A, SCOTT C, ANG KK, FU KK: Cost-utility analysis of RTOG90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head neck squamous cell carcinoma. Intl: Radiat. Omni Biel. Phys. (2001) 51(S1):48.
   Google Scholar
• SHIPLEY WU, LU JD, PILEPICH MVet al.: Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. Int. I Radiat. Once]. Biel Phys. (2002) 54(5):1302–310.
   Google Scholar
• PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. .1. Radiat. Omni Biel. Phys. (2001) 50(5):1243–252.
   Google Scholar
• KONSKI AA, SHERMAN E, KRAHN M et al.: Monte Carlo simulation of a Markov Model for a Phase III clinical trial evaluating the addition of total androgen suppression (TAS) to radiation versus radiation alone for locally advanced prostate cancer(RTOG 86–10). Int. I Radiat. Once]. BielPhys. (2003) 57(2 Suppl.):S215–S216.
   Google Scholar
• NAIMARK D, KRAHN MD, NAGLIE G, REDELMEIER DA, DETSKY AS: Primer on medical decision analysis: Part 5 —Working with Markov processes.Med. Dear. Making (1997) 17(2):152–159.
   Google Scholar
• KRAHN M, RITVO P, IRVINE J et al: Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med. Care (2003) 41(1):153–164.
   PubMedGoogle Scholar
• HARTSELL WE SCOTT C,BRUNER DW et al.: Phase III randomized trial of 8 Gy in 1 fraction versus 30 Gy in 10 fractions for palliation of painful bone metastases: preliminary results of RTOG 97–14. bit.j Radiat. Omni Biel Phys. (2003) 57(2 Suppl.):S124.
   Google Scholar
• http://www.RTOG.orgThe Radiation Therapy Oncology Group homepage.
   Google Scholar